Product name | Recombinant Human VEGFR-2/KDR/CD309 Protein |
---|---|
Catalog No. | RP00084 |
Description | Recombinant Human VEGFR-2/KDR/CD309 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala20-Glu764) of human VEGF R2/KDR (Accession #NP_002244.1) fused with a 6×His tag at the C-terminus. |
Bio-Activity | 1.Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells(HUVEC). The ED50 for this effect is typically 10-50 μg/mL in the presence of 10 ng/mL recombinant human VEGF165. 2.Measured by its binding ability in a functional ELISA. Immobilized PE anti-human CD309 (VEGFR2) Antibody at 1 μg/mL (25 μL/well) can bind Human VEGFR2 with a linear range of 0.46-68.8 ng/mL. |
Purity | > 97% by SDS-PAGE. |
Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
Species | Human |
Calculated MW | 84.11 kDa |
Synonym | CD309; FLK1; VEGFR; VEGFR2; VEGF Receptor 2; KDR |
---|---|
Expression Host | HEK293 cells |
Tag | C-His |
Swiss-Prot | |
Gene ID |
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
* For research use only. Not for therapeutic or diagnostic purposes.